Skip to main content

RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY

Objective

In the past five years, RNA therapeutics have witnessed a true revolution. Several RNA-based therapies have been approved for the treatment of genetic diseases, with unprecedented successes, as in spinal muscular atrophy. Moreover, the past year showed the world that RNA-based therapies, namely mRNA vaccines, can be the answer to a worldwide pandemic and save the lives of millions. RNA therapies are however lagging behind in clinical oncology. The overarching aim of this multi-armed project is to develop RNA-based cancer treatments.
In parallel, the development of immune checkpoint inhibitors has revolutionized cancer care, but its success remains limited to a subset of patients. Altogether, for 60 percent of the eight million new cancer patients diagnosed in Europe each year, including almost all children with solid tumors, there is no EMA- or FDA-approved immunotherapy option, and they are left out of the circle of hope.
In response, CANCERNA aims to build on these two breakthroughs and apply RNA-based therapeutics to overcome key barriers to unfold successful anti-cancer immune responses. Our two key objectives are: on one hand, harness the modulation of RNA processing to enhance the accessibility and immune susceptibility of the tumour and its microenvironment. While on the other hand, enhance the activity of the immune system by retargeting immune effector cells, modulating RNA splicing of key immune receptors and developing personalized mRNA vaccines. The project will focus on two cancer types harboring splicing factor mutations and being generally refractory to immunotherapy: acute myeloid leukemia, relevant for pediatric cancer, and uveal melanoma.
The collective knowledge of our consortium of RNA scientists, clinicians and biotech-pharma experts in RNA processing, RNA drug design and delivery, biocomputing and immuno-oncology provides a unique opportunity to significantly advance novel RNA technologies into successful cancer therapies.

Coordinator

HADASSAH MEDICAL ORGANIZATION
Net EU contribution
€ 877 500,00
Other funding
€ 0,00

Participants (12)

BAR ILAN UNIVERSITY
Israel
Net EU contribution
€ 301 500,00
Address
Bar Ilan University Campus
52900 Ramat Gan

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
FUNDACIO CENTRE DE REGULACIO GENOMICA
Spain
Net EU contribution
€ 511 325,00
Address
Carrer Doctor Aiguader 88
08003 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00
GSAP BIOMED LTD
Israel
Net EU contribution
€ 257 500,00
Address
1 Penguin
000 Shave Zion

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
Net EU contribution
€ 800 690,00
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
IMMUNYX PHARMA LTD
Israel
Net EU contribution
€ 252 656,00
Address
Professor Racah Blvd Givat Ram
9370641 Jerusalem

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,25
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Portugal
Net EU contribution
€ 550 625,00
Address
Avenida Prof Egas Moniz
1649 028 Lisboa

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Research Organisations
Other funding
€ 0,00
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Spain
Net EU contribution
€ 350 500,00
Address
Carretera De Can Ruti Cami De Les Escoles S/n
08916 Badalona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00
MERCK HEALTHCARE KGAA
Germany
Net EU contribution
€ 350 937,50
Address
Frankfurter Strasse 250
64293 Darmstadt

See on map

Region
Darmstadt Darmstadt, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

INTER-LAB LTD.
Israel
Net EU contribution
€ 213 542,50
Address
Hakishon 18
8122004 Yavne

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
STICHTING VUMC
Netherlands
Net EU contribution
€ 482 145,00
Address
De Boelelaan 1117
1081 HV Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Research Organisations
Other funding
€ 0,00
UNIVERSITATSKLINIKUM ERLANGEN
Germany
Net EU contribution
€ 751 710,00
Address
Maximiliansplatz 2
91054 Erlangen

See on map

Region
Bayern Mittelfranken Erlangen, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITEIT ANTWERPEN
Belgium
Net EU contribution
€ 298 750,00
Address
Prinsstraat 13
2000 Antwerpen

See on map

Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00